



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Summary of Main Points from the Meeting held on Monday 17<sup>th</sup> June 2019**

**2. Minutes and Summary Notes from last meeting**

The Minutes and Summary notes from the 15<sup>th</sup> April 2019 Medicines Group meeting were approved and will be circulated. It was noted that there was no meeting held in May.

**3. Matters Arising**

The Group noted the matters arising from the previous meeting.

**4. Business to be transacted by the Medicines Group**

**a) Formulary Applications**

***Full Applications***

***Full Applications***

• **Mannitol Inhalation power in capsule (Osmohale<sup>®</sup>) 0mg, 5mg, 10mg 20mg and 40mg Capsules**

Requested by Thoracic Medicine. Osmohale<sup>®</sup> is indicated for identifying bronchial hyperresponsiveness in subjects with a baseline forced expiratory volume in one second (FEV1) of 70% or more of the predicted value.

It is intended that Osmohale<sup>®</sup> will be used in adult patients at the WMUH Site only. This test would aid diagnosis of suspected asthma patients who don't respond to inhaler treatment and present with on-going asthmatic symptoms. The test will be performed by a qualified respiratory physiologist. Potential cost to the Trust estimated to be £958.80 per annum.

Currently Metacholine is used at the C&W Site for military patients being screened. It is not possible to switch to using Osmohale<sup>®</sup> at present for these patients as Metacoline is considered to be the Gold Standard for screening in accordance with Military regulations which is unlikely to change over the next 2-3 years. The C&W Site do not currently screen non-military patients but would look to use Osmohale<sup>®</sup> if this was to change in the future.

**Decision: Approved for addition to the formulary**

***Ex-panel***

• **Methylphenidate 5mg SR Capsules (Medikinet XL<sup>®</sup>)**

Requested by Paediatrics for a young patient with ADHD who has very difficult behavioural problems and the Consultant Neurologist wishes to initiate on a very small dose.

Medikinet XL<sup>®</sup> 10mg capsules are already included on the formulary.

**Decision: Approved for addition to the formulary**

• **Ciclosporin 0.1% Eye drops (Verkazia<sup>®</sup>)**

Requested by Paediatric Ophthalmology.

Licensed for the treatment of severe Vernal Keratoconjunctivitis (VKC) in children from 4 years of age to 18 years. Not licensed in Adults.

The proposal is to add this to the formulary for treatment of 4-18 age range. Ciclosporin 0.1% Eye drops (Ikervis<sup>®</sup>) will remain on the formulary for the treatment of adult patients

**Decision: Approved for addition to the formulary for prescribing to 4-18 year patient age group**

***Removals***

Nil

***NICE Approved drug applications***

- **TA563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer**



Approved by NICE in February 2019. Approved by Chair's action on 22/05/2019.

**Decision: Approved for addition to the formulary**

- **TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib**

Approved by NICE in March 2019

**Decision: Approved for addition to the formulary**

- **TA572 - Ertugliflozin as monotherapy or with metformin for treating Type 2 Diabetes**

Approved by NICE in March 2019

**Decision: Approved for addition to the formulary**

#### ***Pharmacoeconomic Board requests***

- **Lomustine for Lymphoma**

Approved by the Pharmacoeconomic Board on 11/04/19

For noting by the Group.

**Decision: Noted**

- **Certolizumab for Ankylosing Spondylitis**

Approved by the Pharmacoeconomic Board on 29/04/19

For noting by the Group

**Decision: Noted**

- **Adalimumab for IBD**

Approved by the Pharmacoeconomic Board on 03/05/19

For noting by the Group

**Decision: Noted**

- **Adalimumab for Crohn's Disease**

Approved by the Pharmacoeconomic Board on 15/05/19

For noting by the Group

**Decision: Noted**

- **BMP for fracture of Tibia and Fibula**

Approved by the Pharmacoeconomic Board on 15/05/19

For noting by the Group

**Decision: Noted**

- **Teriparatide for Atypical Fractures**

Approved by the Pharmacoeconomic Board on 15/05/19

For noting by the Group

**Decision: Noted**

#### **4.2 Trust Medicines Policy**

- **NICE NG5 Medicines Optimisation - Gap Analysis and Action plan**

Gap analysis undertaken as part of the Triennial review of the Trust compliance status with NICE *NG5 – Medicines Optimisation: The safe and effective use of medicines to enable the best possible outcomes.*

Areas of non-compliance identified have been addressed by means of an action plan. All actions have been completed or are in progress under a different Trust agenda. The Trust continues to be is compliant with NICE Guidance NG5. Gap analysis and completed action plan will be forwarded to Clinical Governance for official recording of Trust compliance status and archiving.

**Decision: Approved and declaration noted that the Trust remains compliant with NICE Guidance NG5**

**Medicines Optimisation: *The safe and effective use of medicines to enable the best possible outcomes.***

- **TMP: Section 10 - Admission and Discharge**

Updated in line with *NG5 - The safe and effective use of medicines to enable the best possible outcomes*



Information on patient admission that was included in Section 2 Prescribing has been moved into this section and the section renamed as "Admission and Discharge"

**Decision: Approved**

- **RPSGB and RCN Professional Guidance on the Administration of Medicines in Healthcare Settings**

Gap analysis undertaken to review the Trust compliance status *with RPSGB/RCN Professional Guidance on the Administration of Medicines in Healthcare Settings*. Areas of non-compliance identified have been addressed by means of an action plan. Some of the actions were signed off as completed at TMG April 2019 meeting. Last remaining actions have now been completed. The Trust is therefore compliant with RPSGB/RCN Guidance. Gap analysis and completed action plan will be forwarded to Clinical Governance for official recording of Trust compliance status and archiving.

**Decision: Approved and declaration noted that the Trust is compliant with RPSGB and RCN Professional Guidance on the Administration of Medicines in Healthcare Settings**

- **TMP: Section 8 - Administration of medicines**

Updated to clarify the required training and competency for nursing staff to administer medicines. This change closes off an outstanding action identified from the *RPSGB and RCN Professional Guidance on the Administration of Medicines in Healthcare Settings* Gap Analysis.

**Decision: Approved**

- **Risk assessment for the supply of over-labelled medication to GUM out-patients by Registered Nurses and Health Advisors without a second accuracy check**

Risk assessment for the supply of over-labelled medication to GUM out-patients by Registered Nurses and Health Advisors without a second accuracy check which is a practice that is not in line with the Trust Medicines Policy. This risk assessment documents this practice to be low risk. Drafting and approval of this risk assessment closes off an outstanding action identified from the *RPSGB and RCN Professional Guidance on the Administration of Medicines in Healthcare Settings* Gap Analysis.

**Decision: Approved**

- **RPSGB and RCN Professional Guidance on the safe and secure handling of Medicines in Healthcare Settings (Appendix B - Controlled Drugs)**

Gap analysis undertaken to review the Trust compliance status with *RPSGB/RCN Professional Guidance on the safe and secure handling of medicines in healthcare settings - Appendix B* which relates specifically to controlled drugs. There were no areas of non-compliance identified. The Trust is fully compliant with these standards.

**Decision: Approved**

- **TMP: Section 6 - Controlled Drugs**

Table on page 4 updated to include an additional column that details the witnessed destruction requirements for controlled drugs.

Updated to include the need to inform the Trust Caldicott Guardian if there is a need to disclose any information regarding a patient who has been admitted with illicit drugs in their possession.

**Decision: Approved**

- **TMP: Section 5 - Handling and transport of medicines**

Updated in light of the introduction of the role of the Nursing Associate and Apprentice Nursing Associate around collection of medicines (non-CDs) from Pharmacy.

**Decision: Approved**

- **Patient Group Direction Audit Tool**

Audit Tool forms part of TMP Section 21 Patient Group Directions. Updated to include a standard relating to PGD owners maintaining a list of staff who have been deemed competent to work under PGD.

**Decision: Approved**

- **Trust Medicines Policy Audit 2018 - Audit Action Plan**

Action plan for Trust Medicines Policy MP Audit 2018. Updated to include progress with completion of the actions. All actions now completed and noted by the Group



**Decision: Approved**

• **Trust Medicines Policy Audit 2019 - Audit Plan**

Audit plan for Trust Medicines Policy Audit 2019. Audit will be undertaken in July/August 2019 and presented at the TMG meeting September 2019. It was agreed that the target compliance score should be changed from 100% to 90%.

**Decision: Approved**

**4.3 Medicines Optimisation**

• **Trust Annual Medicines Optimisation Report 2018-19**

Medicines management encompasses a range of activities intended to improve the way that medicines are selected, procured, prescribed, dispensed and administered.

This report summarises the activities of groups responsible for the management of medicines at CWFT including the Trust Medicines Group and the groups that feed into the Trust Medicines Group, describes developments throughout the 2018-19 year and reports on results of external assessments.

The Group were asked to forward any comments on the content by 28/06/2019

The finalised report will be forwarded to the Trust Patient Safety Group for noting.

**Decision: Approved**

**4.4 NICE Technical Appraisals and Guidance**

**a) NICE Technical Appraisals**

**1 Additional appraisal published in March 2019**

**5 Appraisals published in April 2019**

**4 Appraisals published in May 2019**

**TA572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes**

**Formulary status / Action**

**Added to the formulary following receipt of a signed application form from the Endocrinology Team.  
(Form included under Section 4.1)**

**TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma**

**Formulary status / Action**

**Currently included on the formulary for other indication.**

**Formulary to be updated accordingly**

**TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis**

**Formulary status / Action**

**Currently included on the formulary for other indication.**

**Formulary to be updated accordingly**

**TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis**

**Formulary status / Action**

**Add to the formulary following receipt of a signed application form from the Dermatology Team.**

**TA576 - Bosutinib for untreated chronic myeloid leukaemia (Terminated appraisal)**

**Formulary status / Action**

**Nil - Terminated appraisal**

**TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma**

**Currently included on the formulary for other indication.**

**Formulary to be updated accordingly**

**TA578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation**

**Formulary status / Action**

**Add to the formulary following receipt of a signed application form from the CW Oncology Team.**



**TA579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy**

**Formulary status / Action**

**Currently included on the formulary for other indication.**

**Formulary to be updated accordingly**

**TA580 - Enzalutamide for hormone-relapsed non-metastatic prostate cancer**

**Formulary status / Action**

**Nil - Not recommended**

**TA581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma**

**Currently included on the formulary for other indication.**

**Formulary to be updated accordingly**

**b) NICE Highly Specialised Technologies published since last meeting**

**1 Highly Specialised Technology published in May 2019**

**HST9 - Inotersen for treating hereditary transthyretin amyloidosis**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**c) NICE Adherence Table (TAs) 2018-19**

NICE adherence Table for NICE TA Guidance published in 2018-19

**Decision: Approved and will be uploaded on the Trust Internet Website**

**d) NICE Adherence Table (HSTs) 2018-19**

NICE adherence Table for NICE HST Guidance published in 2018-19

**Decision: Approved and will be uploaded on the Trust Internet Website**

**4.5 IVIG requests**

**• IVIG issues for April 2019 - CW site**

There were 6 IVIG issues in April 2019, with 2 new requests

**Decision: Approved**

**• IVIG issues for May 2019 - CWH site**

There were 13 IVIG issues in May 2019, with 8 new requests

**Decision: Approved**

**• IVIG issues for April 2019 - WMUH site**

There were 19 IVIG issues in April 2019, with 5 new requests

**Decision: Approved**

**• IVIG issues for May 2019 - WMUH site**

There were 18 IVIG issues in April 2019, with 4 new requests

**Decision: Approved**

**4.6 Items for noting**

**• NHS England: Revised Commissioning Criteria for the use of Immunoglobulins - Letter and Guidance**

NHS England: revised commissioning criteria relating to the use of immunoglobulins.

**Decision: Noted**



- **Quarterly Controlled Drug Summary Report - Q4 2018/19**  
Quarterly Controlled Drug Summary report for Q4 2018/19  
**Decision: Noted**
- **Quarterly Controlled Drugs Accountable Officer Report - Q4 2018/19**  
Quarterly CD Accountable Officer report for Q4 2018/19  
**Decision: Noted**
- **Patient Safety Group Report - April 2019**  
Patient Safety Group Report - April 2019  
**Decision: Noted**
- **Medication Safety Bulletin - Fluoroquinolones**  
Medication Safety Bulletin re Fluoroquinolones  
**Decision: Noted**
- **Medication Safety Bulletin - VTE Prevention**  
Medication Safety Bulletin re VTE prevention  
**Decision: Noted**
- **Annual Pharmacy Clinical Audit Programme 2019-20**  
Annual Pharmacy Clinical Audit for 2019-20  
**Decision: Noted**
- **Trust Non-Medical Prescribing Register - April 2019**  
Trust Non-Medical Prescribing Register - April 2019  
**Decision: Noted**
- **MHRA Drug Safety Update - April 2019**  
MHRA update for April 2019  
**Decision: Noted**
- **MHRA Drug Safety Update - May 2019**  
MHRA update for May 2019  
**Decision: Noted**

#### **4.7 Meeting minutes for noting**

- **Medication Safety Group - March 2019**  
Minutes from Medication safety Group - March 2019  
**Decision: Noted**
- **HIV/GUM Directorate - Medicines Sub-Group Meeting - April 2019**  
Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - March 2019  
**Decision: Noted**

#### **4.8 Additional papers to go to Trust Patient Safety Group**

- Medicines Optimisation Annual Report 2018-2019
- Quarterly Controlled Drug Summary Report - Q4 2018/19
- Quarterly Controlled Drugs Accountable Officer Report - Q4 2018/19
- Patient Safety Group Report - April 2019

#### **5. Any other business**

Nil



**6. Date of next meeting**

**Date: Monday 22<sup>nd</sup> July 2019**

**Time: 8am-9am**

**Location: Executive Board Room (CWH Site) and Accident & Emergency Meeting Room (WMUH Site via video conferencing)**

**Closing date: 28<sup>th</sup> June 2019**